Stay in touch
Join our mailing list to receive regular news on IASO events and activities
IASO responds to consultation on the post-2015 agenda
IASO responsed to the High Level Panel report “A New GlobalPartnership: Eradicate Poverty and Transform Economies through Sustainable Development” and primarily raised concern about the lack of attention to the rising epidemic of obesity in less developed economies and the absence of any specifc obesity related health target.
Full response available here
IASO co-signs statement to the WHO European Ministerial Conference on Nutrition and Non-Communicable Diseases
The statement calls for Member States and WHO to consider three key recommendations for tackling diet-related NCDs
Ensure a healthier media environment for our children
Create a healthy food environment in schools
- Improve the quality of the food supply
Other signatories of the statement include World Cancer Research Fund International (WCRF-Int), European Heart Network (EHN), International Diabetes Federation (IDF), The NCD Alliance, The European Consumers' Organisation (BEUC), European Public Health Alliance (EPHA)
The full statement can be downloaded here
Is obesity a disease?
IASO responds to discussions on whether or not obesity should be classified as a disease.
The American Medical Association has announced this week that it now recognises obesity as a disease (1). In coming to this decision it concluded that ‘recognizing obesity as a disease will help change the way the medical community tackles this complex issue that affects approximately one in three Americans’. Arguments against the classification of obesity as a disease have been made on the grounds that obesity is more a risk factor for other conditions than a disease in its own right and that ‘medicalizing’ obesity by declaring it a disease would define one-third of Americans as being ill and could lead to more reliance on costly drugs and surgery rather than lifestyle changes.
Can you help us?
Donate towards better clinical care...
Gillian Shepherd worked for over 20 years to improve the medical management of obesity. She worked originally for Boots before her group was transferred to work for Knoll and then Abbott. She played a pivotal role in ensuring that patients received the best and safest treatment available to them.
She was a key scientist developing proper clinical trials for the drug, sibutramine, and organised major teaching sessions around the world. She helped in developing a simplified form of dietary and physical activity management, tested in 10,000 patients in 16 countries. This became the standard for assessing better ways of providing clinical care. All funds contributed in her memory will go towards continuing her quest for better clinical care.
To see our latest links to obesity news on the internet click here.